MPS Pharmaa has informed that pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, the Board of Directors of the Company in its meeting held on Tuesday, 13th August, 2024 at 12:00 pm at the corporate office of the company at 703, Arunachal Building, 19, Barakhamba Road, Connaught Place, New Delhi -110001 and concluded at 01:58 P.M has transacted the following business: 1. Considered and Approved the Standalone Un-audited Financial Results of the Company for the quarter ended 30th June, 2024. 2. Considered and Approved the Limited Review Report for the Un-audited Financial Results of the Company for the quarter ended 30th June, 2024. Further pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, a copy of the aforesaid Un-audited Financial Results for the quarter ended 30th June, 2024 along with Limited Review Report thereon is enclosed.
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1714.25 |
Dr. Reddys Lab | 1149.75 |
Cipla | 1452.70 |
Lupin | 2009.40 |
Zydus Lifesciences | 891.25 |
View more.. |